Skip to content

Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization

Efficacy and safety of antiplatelet drugs in patients with moyamoya disease after revascularization

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100046178
Enrollment
Unknown
Registered
2021-05-08
Start date
2021-05-10
Completion date
Unknown
Last updated
2021-12-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moyamoya disease

Interventions

Taking aspirin group:Nil

Sponsors

Qilu Hospital of Shandong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
No minimum to 60 Years

Inclusion criteria

Inclusion criteria: 1. Moyamoya disease diagnosed by DSA; 2. Transient ischemic attack or cerebral infarction was the first clinical manifestation; 3. CT cerebral perfusion examination showed obvious cerebral perfusion damage; 4. There was no abnormal coagulation function.

Exclusion criteria

Exclusion criteria: 1. Combined with other serious medical conditions affecting outcomes, such as atrial septal defect and atrial fibrillation, affected the outcome; 2. Combined with cerebral hemorrhage / subarachnoid hemorrhage; 3. Aged over 60 years old; 4. Aged 50 to 60 years old, combined with hypertension, diabetes, coronary heart disease and hyperlipidemia.

Design outcomes

Primary

MeasureTime frame
Postoperative stroke / TIA events;Bleeding events;

Secondary

MeasureTime frame
Postoperative Matsushima grading;ADR;Postoperative epilepsy events;

Countries

china

Contacts

Public ContactXiang Yanxiao

Qilu Hospital of Shandong University

11xiaoxiao23@163.com+86 18560083562

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026